Needham analyst Mike Matson raised the firm’s price target on Masimo to $173 from $149 and keeps a Buy rating on the shares. At its upcoming investor day next week, the company is expected to provide an overview of its Healthcare and Non-Healthcare businesses, strategy, pipeline, and long-term financial targets, the analyst tells investors in a research note. Matson adds that Masimo’s 2022E-2024 estimates are reasonable and likely to prove conservative.
Published first on TheFly